Regeneron Wins Expanded Eylea Approval for CRVO
The FDA Friday approved a second indication for Regeneron Pharmaceuticals’ Eylea to treat macular edema following central retinal vein occlusion (CRVO).
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.